诺和诺德斥资最高13.3亿美元获Nanexa药物递送技术独家许可Novo Nordisk Signs Up to $1.33 Billion Deal for Nanexa Drug Delivery Platform
瑞典药物递送企业Nanexa宣布与丹麦制药巨头诺和诺德达成一项总金额最高可达13.3亿美元的全球独家许可协议。根据双方约定，诺和诺德获得在最多五个研发项目中独家应用Nanexa旗下PharmaShell长效药物递送技术的权利，重点面向肥胖症、2型糖尿病以及其他心脏代谢相关疾病领域推进长效注射剂型研发。两家公司计划通过该技术改善药物体内释放表现，实现按月或按季度的给药频次。 根据公开协议条款，Nanexa将有资格获得约7亿美元的首付款，并有望随着后续研发和监管里程碑的达成获取额外款项，未来相关产品上市后还将享有低个位数的销售特许权使用费。受该项重大合作消息带动，在斯德哥尔摩纳斯达克第一北方成长市场交易的Nanexa股票周五开盘飙升超过150%，盘中涨幅收窄至约114%。这项交易所带来的资金规模较Nanexa在2025年录得的约389万美元全年营收形成鲜明对比，为这家微盘生物技术企业拓展平台技术与推进管线提供了关键财务支撑。
Swedish drug delivery company Nanexa has entered into a global exclusive licensing agreement with pharmaceutical giant Novo Nordisk valued at up to $1.33 billion. Under the terms announced after Thursday's market close, the maker of Wegovy and Ozempic secures exclusive rights to utilize Nanexa's PharmaShell delivery platform across up to five development programs. The collaboration focuses on long-acting injectable therapies for obesity, type 2 diabetes, and other cardiometabolic conditions, with both companies aiming to enable monthly or quarterly dosing schedules through controlled-release technology. Nanexa is eligible to receive an upfront payment of approximately $700 million, alongside potential development and regulatory milestone payments, and low single-digit royalties on future commercial sales. Following the announcement, shares of the microcap developer surged more than 150% at the open on Stockholm's Nasdaq First North Growth Market before settling to a gain of around 114%. The potential cash infusion represents a massive transformation for Nanexa, which generated roughly $3.89 million in full-year revenue for 2025, providing substantial financial resources as it seeks to validate its platform and expand applications into additional therapeutic areas.
01交易概况与核心财务条款Deal Overview and Core Financial Terms
在周四收盘后公布的许可合作中，诺和诺德与Nanexa达成整体估值最高达13.3亿美元（约合13亿美元）的全球协议。该项交易设立了以研发进展和商业化进程为基准的分阶段付款架构，使Nanexa能够通过技术授权直接接入大型药企的管线资源与资本支持。
Under the global licensing agreement announced following Thursday's market close, Novo Nordisk committed to a structured deal framework valued at up to $1.33 billion (around $1.3 billion) with Nanexa. The transaction establishes a multi-tiered payment schedule that ties substantial financial disbursements directly to development progression and future commercialization milestones.
按照合约具体财务分配，Nanexa有资格获得约7亿美元的初始首付款项，其余资金则取决于产品研发阶段以及监管审批等既定里程碑目标的达成情况。除前期及阶段性资金外，协议还明确 Nanexa 将在未来相关获批产品推向市场后，持续获得按净销售额计算的低个位数特许权使用费。
The financial terms specify that Nanexa is eligible to receive an upfront cash payment of approximately $700 million upon entering the collaboration. The remaining transaction value comprises conditional milestone payments tied to specific drug development achievements and regulatory approvals, alongside continuous low single-digit royalties on any future net commercial sales generated by the licensed products.
02PharmaShell技术细节与研发目标PharmaShell Technology and Target Indications
在本次达成的合作框架下，诺和诺德获得了将Nanexa专有PharmaShell技术独家应用于最多五个研发项目的权利。该技术的核心机理是在药物微粒表面包裹一层无机超薄涂层，从而精确控制药物在生物体内的释放速率与时长，实现长效注射制剂的平稳释放。
Under the licensing partnership, Novo Nordisk secured exclusive access to incorporate Nanexa's proprietary PharmaShell platform across up to five distinct development programs. The drug delivery system functions by applying an ultra-thin inorganic coating directly onto active drug particles, enabling precise control over sustained release rates and therapeutic dispersion profiles within the body over extended durations.
双方将研发重心集中在肥胖症、2型糖尿病及其他心脏代谢疾病领域，力求将现有及新型候选药物的给药间隔大幅延长。该合作旨在开发出能够维持每月一次或每季度一次给药频次的长效注射疗法，从而降低患者的日常注射频率并提升治疗依从性。
The joint development efforts directly address key therapeutic indications, centering on treatments for obesity, type 2 diabetes, and wider cardiometabolic conditions. By applying this controlled-release technology to long-acting injectable candidates, the companies aim to achieve dosing schedules requiring administration only once per month or once per quarter, lowering patient injection burdens compared to more frequent regimens.
03资本市场反应与Nanexa财务背景Market Reaction and Nanexa Financial Context
周五早盘，在斯德哥尔摩纳斯达克第一北方成长市场挂牌的Nanexa股价出现大幅异动。开盘后该股一度暴涨超过150%，随后到当地时间上午11点50分涨幅稳定在约114%附近，使其股价距2015年11月创下的历史峰值仅差约12%。
Nanexa shares registered sharp gains on the Nasdaq First North Growth Market in Stockholm during early trading on Friday. Following an opening spike exceeding 150%, the microcap stock moderated to a 114% advance by 11:50 a.m. local time, positioning the equity approximately 12% below its previous all-time peak established in November 2015.
此次来自诺和诺德的巨额许可协议规模与Nanexa现有的业务体量形成鲜明反差。这家瑞典微盘生物技术公司公布的财报显示，其2025年全年营收仅约为389万美元，虽然这一数字较前一年实现了48.4%的增长，但潜在的前期付款及里程碑总金额仍数倍于其年度营收基数。
The multi-million-dollar structure under the Novo Nordisk agreement contrasts sharply with the Swedish biotech developer's baseline operational scale. Nanexa reported full-year revenues of roughly $3.89 million for 2025, which marked a 48.4% increase over the previous year, underscoring the massive financial scale of the potential upfront cash and subsequent milestone allocations.
04管理层表态与未来战略发展Management Statements and Future Strategy
Nanexa董事长Göran Ando表示，借助与诺和诺德达成的许可协议，公司步入了一个具备可观财务实力的新发展阶段。这些财务资源将协助公司把独有的原子层沉积技术大幅扩展至其他治疗领域，并为建立具备可持续性的长期业务架构创造关键条件。
Nanexa Chair Göran Ando stated that the collaboration with Novo Nordisk ushers the drug-delivery developer into a new operating era characterized by substantial financial strength. He emphasized that the capital resources provide the company an opportunity to build a sustainable long-term business while significantly expanding applications of its proprietary atomic layer deposition technology across other therapeutic areas.
Nanexa首席执行官David Westburg指出，该协议为推进PharmaShell技术进入更多疾病治疗方向奠定了坚实基础。他强调，公司将选择性推进更多内部研发项目迈向临床概念验证阶段，从而依托PharmaShell技术平台的广度捕获更高产业价值。
Nanexa Chief Executive Officer David Westburg noted that the transaction establishes a solid foundation for broadening PharmaShell deployments into additional medical fields. Westburg added that the partnership enables the biotech firm to selectively advance internal pipeline programs toward clinical proof of concept, positioning the organization to capture enhanced commercial value from the overall scope of the PharmaShell platform.